Fmr LLC Acquires Shares of 3,742 Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Fmr LLC bought a new stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 3,742 shares of the company’s stock, valued at approximately $47,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GYRE. Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the second quarter worth about $218,000. Rhumbline Advisers acquired a new stake in Gyre Therapeutics during the second quarter valued at approximately $123,000. WINTON GROUP Ltd bought a new position in Gyre Therapeutics during the 2nd quarter worth approximately $220,000. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares in the last quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $11.90 on Thursday. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $30.39. The firm’s 50-day moving average is $12.76 and its 200-day moving average is $12.62.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.